Powering Rare Disease Access with Real-World Evidence

10

June

  • 3pm London 10am New York
  • Free

Why attend?

Speakers

Select a speaker to learn more

Back
Dr. Raymond A. Huml, MS, DVM, RAC
Vice President of Rare & Orphan Disease Strategy

Dr. Raymond A. Huml is the Vice President of Rare & Orphan Disease Strategy at Sciensus, with over 30 years in the healthcare and biopharmaceutical industries. A leader in rare disease research and global due diligence, he has driven nearly $3 billion in capital commitments. A prolific author and award-winning expert, he is dedicated to advancing rare disease innovation, diversity, and global healthcare, including his Peace Corps service in Ghana.

  • With over 30 years in the healthcare and biopharmaceutical industries
  • Has driven nearly $3 billion in capital commitments
  • Prolific author and award-winning expert
Next speaker
Back
Noolie Gregory, BSc
Head of Evidence Generation

Noolie Gregory is a seasoned professional with over 20 years of experience in the pharmaceutical and Contract Research Organisation (CRO) sectors. With expertise spanning Clinical Development, Medical Affairs, Real World and Late Phase studies, and Early Access Programs, and has a proven track record of driving impactful results across diverse therapeutic areas.

In recent years, Noolie has focused on leveraging patient- and site-facing technologies to ensure patient-centered design and accelerate the delivery of clinical studies. Her dedication to improving study execution and patient experience has made a significant impact in the field. Notably, Noolie has extensive experience in oncology and has played a pivotal role in the development of several major medicines.

In her role of Head of Evidence Generation Noolie is working across all the Sciensus services lines to enable evidence generation services to support our clients to maximise their patient interactions and generate new insights to accelerate medical affairs and launch activities.  The team are working to offer all types of RWLP designs as well as EAPs.

Next speaker
Back
Ross Henry Law
Reporter, Global Data PLC

Ross Henry Law is a reporter for GlobalData's healthcare publications. His key interest areas in healthcare include regulation, mental health, neurology, oncology, and Alzheimer's disease. Ross also has extensive prior experience in covering the captive insurance, retail, and technology sectors.

Next speaker
Back
Chris Hoyle, Ph.D, MS, BSc
Head Market Access, Pricing & HEOR, Immunocore

Chris has over 25 years of experience in the pharmaceutical industry. Over the past 10 years, he has focused on Market Access, Pricing, and Health Economics and Outcomes Research (HEOR), particularly in oncology. He is the Head of Market Access, Pricing, and HEOR for ex-US countries at Immunocore, a small biotech company based in Oxford (UK) and Rockville (USA). Chris is responsible for negotiating reimbursement and access across more than 30 countries.

Immunocore, which originated from Oxford University over 25 years ago, recently launched its first oncology medicine, tebentafusp, for the treatment of a rare cancer with no standard of care and a short life expectancy. The exceptional achievements of Immunocore and tebentafusp were recognised with the prestigious Prix Galien awards in both France and Germany. The launch is regarded as one of the most successful first launches for a biotech company.

Prior to joining Immunocore, Chris supported oncology efforts at AstraZeneca. Before moving into Market Access, he worked in research at GSK and SmithKline Beecham, and in pathology within the UK NHS. Chris holds a master’s degree in Economic Evaluation in Healthcare and a PhD in Biochemistry.

 

Next speaker

Enquiry